On May 22, 2018 Lupagen, Inc. (www.lupagen.com), a medical device company developing first-in-class cell and gene therapy delivery technologies for CAR-T, gene editing and immunotherapy products, reported the intent to explore the development of a bedside, point-of-care delivered CAR-T therapy with Humanigen, Inc. (OTCQB: HGEN), a biopharmaceutical company developing cutting-edge CAR-T optimization and oncology treatments (Press release, Lupagen, MAY 22, 2018, View Source;humanigen-to-explore-point-of-care-car-t-therapy-300652016.html [SID1234573190]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Lupagen and Humanigen are planning work to investigate the potential of a bedside CAR-T therapy created from Humanigen’s Ifabotuzumab, a first-in-class, monoclonal antibody targeting the EphA3 receptor tyrosine kinase.

"We are excited to support Humanigen’s strategic objectives to deliver safer, more effective and more routine CAR-T treatments, including one with the novel EphA3 target," said Nipon Das, M.D., chief executive officer and co-founder of Lupagen. "A bedside, closed-loop, point-of-care patient-connected system allows patient cells to be harvested, reprogrammed or modified, then reinfused at the bedside. The potential positive impact on CAR-T and other ex-vivo autologous cell and gene therapies is enormous through lower treatment costs, increased patient access and enhanced safety and control of these powerful new therapies."